LUPUS NEPHRITIS

This is an early-stage study testing a new type of cell therapy called Prula-cel for adults with severe autoimmune diseases that haven't responded well to standard treatments. The therapy involves giving patients specially engineered immune cells designed to target and remove har…

This study aimed to test if an investigational drug called nipocalimab could help control kidney damage in adults with active lupus nephritis. It was designed to work by lowering levels of harmful antibodies that attack the kidneys. The trial was a Phase 2 study that was withdraw…

This early-stage study aimed to test the safety and initial effects of a single infusion of CB-010, a new type of cell therapy modified with CRISPR gene-editing, in adults with severe lupus that hasn't responded to standard treatments. The trial was designed to last about two yea…

This is an early-stage study testing a new personalized cell therapy called KITE-363 for people with severe autoimmune diseases that haven't improved with standard treatments. The therapy involves modifying a patient's own immune cells to target and remove harmful B cells, which …

This early-stage study is testing a new therapy called KYV-101 for adults with severe lupus nephritis, a serious kidney disease caused by lupus, that hasn't improved with standard treatments. The therapy involves collecting a patient's own immune cells, modifying them in a lab to…

This early-stage study is testing the safety of an experimental drug called felzartamab in 14 people with lupus nephritis, a serious kidney disease caused by lupus. The drug is designed to target specific immune cells that cause harmful inflammation and damage in the kidneys. Res…

This early-stage study is testing a new cell therapy called CNTY-101 in people with severe autoimmune diseases like lupus, lupus nephritis, and scleroderma that have not improved with other treatments. The main goals are to find a safe dose and see if the therapy helps control th…

This study is testing a new drug called povetacicept in adults with several serious autoimmune kidney diseases, including lupus nephritis and IgA nephropathy. The main goals are to see if the drug is safe and if it can help control these diseases. Participants receive injections …

This study is testing whether adding the drug anifrolumab to standard treatment helps adults with active lupus nephritis, a serious kidney disease caused by lupus. About 360 participants will receive either anifrolumab or a placebo (dummy drug) for 76 weeks, followed by an option…

This early-stage study is testing a new treatment called YTB323, a type of CAR-T cell therapy, for people with severe lupus that hasn't responded to other strong medications. The main goals are to see if the treatment is safe and if it can reduce lupus disease activity. Researche…

This early-stage study is testing a new, personalized cell therapy called KYV-101 for adults with severe lupus nephritis, a serious kidney disease caused by lupus, that hasn't responded to other treatments. The therapy involves modifying a patient's own immune cells to target and…

This study tested whether adding the drug obinutuzumab to standard lupus nephritis treatment helps control the disease and protect kidney function better than standard treatment alone. It involved 271 adults with active, serious kidney inflammation caused by lupus. Researchers co…

This early-stage study is testing the safety of a new two-part cell therapy (SYNCAR-001 + STK-009) in adults with severe forms of lupus or scleroderma that haven't responded to other treatments. The therapy involves collecting and modifying a patient's own immune cells (CAR-T cel…